Last reviewed · How we verify
Tacrolimus Lipid Suspension for enema — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Tacrolimus Lipid Suspension for enema (Tacrolimus Lipid Suspension for enema) — Jina Pharmaceuticals Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tacrolimus Lipid Suspension for enema TARGET | Tacrolimus Lipid Suspension for enema | Jina Pharmaceuticals Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tacrolimus Lipid Suspension for enema CI watch — RSS
- Tacrolimus Lipid Suspension for enema CI watch — Atom
- Tacrolimus Lipid Suspension for enema CI watch — JSON
- Tacrolimus Lipid Suspension for enema alone — RSS
Cite this brief
Drug Landscape (2026). Tacrolimus Lipid Suspension for enema — Competitive Intelligence Brief. https://druglandscape.com/ci/tacrolimus-lipid-suspension-for-enema. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab